A lack of junior miner exploration in tough economic times has weighed on drill supplier Imdex, but brokers believe an upswing is not too far off
Amplia Therapeutics is in pursuit of a cancer drug for pancreatic cancer and possibly other indications including ovarian cancer, the New Criterion’s Tim Boreham reports
With the Big Four banks regarded as overvalued, investors are pondering whether there’s better value in their smaller counterparts that trade on more modest valuations but with similar or higher dividend yields
Recently ASX-listed Blinklab claims the world’s best mobile phone app for detecting autism, the New Criterion’s Tim Boreham reports
ARB Corp’s third-quarter performance showcased why shares continue to trade at a premium to the Small Industrials Index
Following a strong run over the last year, brokers see further upside for shares of FleetPartners following first half results
Life360 has doubled in share price since its March earnings result, but brokers believe further re-rating is still on the cards
As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission
SiteMinder’s March quarter update showed the company is on track to reach positive earnings and cash flow next quarter and new product launches offer growth
The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA